Ziping Wei, BlissBio CEO
Eisai’s cancer drug Halaven at the center of $2B pact with BlissBio, like its Bristol Myers ADC deal
Eisai plans to pay up to $2 billion to develop an antibody-drug conjugate with Chinese biotech Bliss Biopharmaceutical, and the Japanese biopharma could gain ex-Greater China rights to the ADC, which includes its cancer med Halaven.
The companies said Monday that Eisai will pay an undisclosed upfront amount to co-develop BB-1701 through an option period, at which point the duo can form a strategic collaboration. The ADC uses Halaven as a payload, with the goal of treating breast, lung and other solid tumors expressing HER2.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters